BioCentury | Jun 21, 2019
Company News

June 20 Company Quick Takes: Priority Review for Alexion, Melinta therapies; plus Alimera, Denovo and more

Priority Review for Alexion's Ultomiris sBLA FDA accepted and granted Priority Review to an sBLA from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) for Ultomiris ravulizumab-cwvz to block complement-mediated thrombotic microangiopathy in patients with atypical hemolytic uremic syndrome....
BioCentury | Jan 18, 2019
Financial News

Acceleron, Stemline price upsized follow-ons

Acceleron Pharma Inc. (NASDAQ:XLRN) and Stemline Therapeutics Inc. (NASDAQ:STML) have each priced upsized follow-ons, as one company prepares for key regulatory submissions and the other conducts its first product launch. Acceleron said Jan. 16 that...
BioCentury | Jan 16, 2019
Financial News

Acceleron, Stemline price upsized follow-ons

Acceleron Pharma Inc. (NASDAQ:XLRN) and Stemline Therapeutics Inc. (NASDAQ:STML) have each priced upsized follow-ons, as one company prepares for key regulatory submissions and the other conducts its first product launch. Acceleron said Wednesday that it...
BioCentury | Mar 21, 2017
Distillery Therapeutics

Neurology

...Patient sample, mouse and cell culture studies suggest ORM2 could help treat neuroinflammation. Levels of ORM2...
...healthy volunteers and normal mice, respectively. In a mouse microglia cell line pretreated with LPS, ORM2...
...Next steps include testing ORM2 in additional models of neuroinflammation and neurodegeneration. TARGET/MARKER/PATHWAY: Orosomucoid 2 (ORM2; AGP2...
BioCentury | Feb 26, 2015
Tools & Techniques

The Power of Two

The goal of chemical libraries is to contain enough molecules that even targets with uncommon binding sites can find the rare compound that binds with high affinity. Rather than synthesizing hundreds of thousands of molecules,...
BioCentury | Feb 26, 2015
Distillery Techniques

Techniques: Dual display DNA-barcoded chemical library screening

Assays and screens TECHNOLOGY: High throughput screening Dual-display DNA-barcoded chemical libraries could be useful for high throughput screening for ligand pairs that could be linked together to form high-affinity compounds. A chemical library of over...
BioCentury | Dec 23, 2013
Company News

Orion, J&J deal

Orion granted Johnson & Johnson's Janssen Pharmaceuticals Inc. subsidiary exclusive, worldwide development rights and ex-European commercialization rights to Orion's adrenergic receptor alpha 2c ( ADRA2C ) antagonists to treat Alzheimer's disease (AD). The deal includes ORM-12741 , which...
BioCentury | Dec 20, 2013
Company News

Orion, J&J in Alzheimer's deal

Orion Corp. (HSE:ORNAV; HSE:ORNBV) granted the Janssen Pharmaceuticals Inc. subsidiary of Johnson & Johnson (NYSE:JNJ) exclusive, worldwide development rights and ex-European commercialization rights to Orion's adrenergic receptor alpha 2c ( ADRA2C ) antagonists to treat Alzheimer's disease....
BioCentury | Sep 26, 2013
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Alkylglycerone phosphate synthase (AGPS) Studies in patient samples and mice suggest inhibiting AGPS could help treat cancer. In tumor samples...
BioCentury | Jul 11, 2013
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Ras; rho guanine nucleotide exchange factors (ARHGEFs; GEFs) An in vitro study suggests prolonged inhibition of interactions between Ras and GEFs could help treat...
Items per page:
1 - 10 of 16